Connect to share and comment

Poland extends corruption probe into Britain's GSK

Polish prosecutors said Monday they have extended a probe into allegations that British pharmaceutical giant GlaxoSmithKline bribed doctors into promoting one of its drugs. The company also faces a bribery probe in China and last week announced it was investigating alleged corruption by staff at its pharmaceuticals division in Iraq.

Poland extends corruption probe into Britain's GSK

Polish prosecutors said Monday they have extended a probe into allegations that British pharmaceutical giant GlaxoSmithKline bribed doctors into promoting one of its drugs. The company also faces a bribery probe in China and last week announced it was investigating alleged corruption by staff at its pharmaceuticals division in Iraq.

GSK faces criminal bribery investigation in Poland

By Ben Hirschler and Adrian Krajewski LONDON/WARSAW (Reuters) - GlaxoSmithKline <GSK.L> is facing a criminal investigation in Poland for allegedly bribing doctors to promote its lung drug Seretide, adding to problems for a company already accused of corruption in China and Iraq. Poland's Central Anti-Corruption Bureau, or CBA, said on Monday that 13 people had been charged in connection with the investigation launched by Polish prosecutors.

Drug giant GSK launches probe into allegations it bribed doctors in Iraq

LONDON - GlaxoSmithKline said Monday it has launched an investigation into allegations it bribed doctors in Iraq, as the pharmaceuticals giant remains embroiled in a major corruption scandal in China. The company said it is probing allegations of "improper conduct in our Iraq business" after reports that it hired 16 doctors and pharmacists in Iraq as paid sales representatives at a time they continued working for the government.

Britain's GSK reveals new bribery probe in Iraq

British drugmaker GlaxoSmithKline (GSK) is investigating alleged corruption by staff at its pharmaceuticals division in Iraq, the group announced on Monday. GSK, which already faces a bribery probe in China, stressed that it would not tolerate illegal behaviour by staff. "We are investigating allegations of improper conduct in our Iraq business. We have zero tolerance for unethical or illegal behaviour," a spokesman told AFP.

Britain's GSK reveals new bribery probe in Iraq

British drugmaker GlaxoSmithKline (GSK) is investigating alleged corruption by staff at its pharmaceuticals division in Iraq, the group announced on Monday. GSK, which already faces a bribery probe in China, stressed that it would not tolerate illegal behaviour by staff. "We are investigating allegations of improper conduct in our Iraq business. We have zero tolerance for unethical or illegal behaviour," a spokesman told AFP.

GlaxoSmithKline sacks some China staff for malpractice: source

LONDON (Reuters) - GlaxoSmithKline, facing allegations of bribery in China, has dismissed some employees in the country over failure to comply with expenses rules, a person familiar with the situation said on Friday. Britain's biggest drugmaker declined to detail the move but confirmed it had stepped up monitoring of expenses claims, resulting in action being taken against some employees.

GlaxoSmithKline throws in towel on lung cancer vaccine trial

By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline Plc (GSK) has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit. The decision comes less than two weeks after GSK said the MAGE-A3 therapeutic vaccine did not help patients with non-small cell lung cancer in the Phase III study overall, but it was still looking for improvements among patients with a particular genetic profile.

British drugs firm GSK announces Africa investment

British pharmaceutical giant GlaxoSmithKline on Monday announced a five-year investment programme for sub-Saharan Africa to fuel the company's growth and to serve an area with "pressing health needs". GSK will invest up to £130 million ($216 million, 157 million euros), including £100 million to expand existing manufacturing operations in Nigeria and Kenya and build up to five new factories in Africa, it said in a statement.

GSK recalls weight-loss drug Alli in U.S. after tampering

LONDON (Reuters) - GlaxoSmithKline is recalling all supplies of its non-prescription weight-loss drug Alli in the United States and Puerto Rico, the company said on Thursday, after reports that some bottles had been tampered with. The British group, which believes that some supplies may not contain authentic Alli, is working with the U.S. Food and Drug Administration on the retailer-level recall. News of the tampering first emerged on Wednesday.
Syndicate content